Definitive Healthcare (NASDAQ:DH) Stock Rating Upgraded by Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

Several other equities analysts also recently commented on the stock. The Goldman Sachs Group increased their price objective on shares of Definitive Healthcare from $3.00 to $3.40 and gave the company a “neutral” rating in a research note on Monday, May 12th. Barclays dropped their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research note on Monday, March 3rd. Finally, BTIG Research downgraded shares of Definitive Healthcare from a “buy” rating to a “neutral” rating in a research note on Friday, May 9th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $5.10.

Definitive Healthcare Stock Performance

Shares of NASDAQ:DH opened at $3.80 on Friday. The company’s 50 day moving average price is $3.17 and its two-hundred day moving average price is $3.69. Definitive Healthcare has a 12-month low of $2.15 and a 12-month high of $6.16. The firm has a market cap of $564.83 million, a PE ratio of -0.87, a PEG ratio of 6.61 and a beta of 1.58. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.37.

Definitive Healthcare (NASDAQ:DH) last announced its earnings results on Thursday, May 8th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Definitive Healthcare had a negative net margin of 206.05% and a positive return on equity of 3.69%. The firm had revenue of $59.19 million for the quarter, compared to analyst estimates of $56.20 million. During the same quarter in the prior year, the business posted $0.08 EPS. The business’s revenue was down 6.8% compared to the same quarter last year. Equities research analysts predict that Definitive Healthcare will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DH. Goldman Sachs Group Inc. raised its position in shares of Definitive Healthcare by 564.2% in the first quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after purchasing an additional 7,404,363 shares during the period. Irenic Capital Management LP raised its position in shares of Definitive Healthcare by 9.2% in the fourth quarter. Irenic Capital Management LP now owns 7,003,194 shares of the company’s stock valued at $28,783,000 after purchasing an additional 590,009 shares during the period. Palisade Capital Management LP raised its position in shares of Definitive Healthcare by 1.3% in the first quarter. Palisade Capital Management LP now owns 2,265,198 shares of the company’s stock valued at $6,546,000 after purchasing an additional 29,774 shares during the period. Dimensional Fund Advisors LP increased its holdings in Definitive Healthcare by 1.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company’s stock worth $7,661,000 after acquiring an additional 23,410 shares during the period. Finally, Geode Capital Management LLC increased its holdings in Definitive Healthcare by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 1,272,660 shares of the company’s stock worth $5,231,000 after acquiring an additional 39,938 shares during the period. 98.67% of the stock is currently owned by hedge funds and other institutional investors.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.